Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians

摘要: Abstract purpose: The objective of this study was to examine the effect low-dose aspirin (325 mg on alternate days) primary prevention angina pectoris in United States Physicians' Health Study. Despite a postulated role platelets atherogenesis and myocardial ischemia, chronic platelet inhibition development clinical is unknown. subjects methods: Study randomized, double-blind, placebo-controlled trial among 22,071 male physicians aged 40 84 years, free from previous infarction, stroke, transient cerebral ischemia at entry, followed for an average 60.2 months. 21,738 who were also baseline constituted population present analyses. results: During 106,652 person-years follow-up, 331 patients with confirmed diagnosed, 194 whom underwent coronary revascularization procedure (coronary artery bypass graft surgery or angioplasty). As compared participants assigned placebo, relative risk group 1.10 (95% confidence interval [CI], 0.88 1.38). For revascularization, 1.19 CI, 1.59). After simultaneous control other factors proportional-hazards model, these risks remained near unity 1.07 0.84 1.36) 1.11 0.81 1.52), respectively. When examined according year randomization trial, there no pattern increasing benefit longer duration treatment. conclusion: These randomized data indicate that months does not reduce incidence pectoris.